Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: A case-control study nested within the French hospital database on HIV ANRS cohort CO4

Archives of Internal Medicine

Volumn 170, Issue 14, 2010, Pages 1228-1238

  Lang, Sylvie ^a,b   Mary Krause, Murielle ^a,b   Cotte, Laurent ^c   Gilquin, Jacques ^d   Partisani, Marialuisa ^e   Simon, Anne ^f   Boccara, Franck ^f   Costagliola, Dominique ^a,b,f  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔTEL DIEU   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FRANCE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; CARBAMATES; CASE-CONTROL STUDIES; COHORT STUDIES; CONFIDENCE INTERVALS; DIDEOXYNUCLEOSIDES; FEMALE; FRANCE; HIV INFECTIONS; HOSPITALS, ISOLATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PHOSPHORIC ACID ESTERS; REGRESSION ANALYSIS; RISK; RITONAVIR; SULFONAMIDES;

EID: 77955296288     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.197     Document Type: Article

References (34)

1. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet. 1998;351(9120):1958- 1959.
2. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors [letter]. Lancet. 1998;351(9112):1328. (Pubitemid 28195913)
3. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17(17):2479-2486.
4. Friis-Møller N, Reiss P, Sabin CA, et al;DADStudy Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-1735.
5. Sabin CA, Worm SW, Weber R, et al; D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417-1426.
6. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22(14):F17-F24.
7. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51(1):20-28.
8. Department of Health and Human Services. Archived guidelines. AIDSinfo Web site. http://www.aidsinfo.nih.gov/Guidelines/ArchivedGuidelines.aspx? MenuItem=Guidelines&Search=Off&GuidelineID=18&ClassID=6. Accessed December 2, 2009.
9. European AIDS Clinical Society (EACS) guidelines. http://www. europeanaidsclinicalsociety.org/guidelines.asp. Accessed December 2, 2009.
10. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS. 2009;23(15):2021-2027.
11. Kristoffersen US, Kofoed K, Kronborg G, Benfield T, Kjaer A, Lebech AM. Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. HIV Med. 2009;10(10):627-633.
12. Smith KY, Patel P, Fine D, et al; HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment (HEAT study). AIDS. 2009;23(12):1547-1556.
13. Satchell C, O'Connor E, Peace A, et al. Platelet hyper-reactivity in HIV-1-infected patients on abacavir-containing ART. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 11, 2009; Montreal, Quebec, Canada. Abstract 151LB.
14. Organisation Mondiale de la santé. Classification Statistique Internationale des Maladies et des Problèmes de santé Connexes, 10th Revision. Geneva, Switzerland: Organisation Mondiale de la Santé; 1993.
15. Yeni P. Rapport 2008: Prise en charge médicale des patients infectés par le VIH. Paris, France: Medecine-Sciences, Flammarion; 2008.
16. Luepker RV, Apple FS, Christenson RH, et al; AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. Circulation. 2003;108(20):2543-2549.
17. Guiguet M, Mary-Krause M, Ename B, Costagliola D, Grabar S. Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4). Pharmacoepidemiol Drug Saf. 2008;17(5):468-474.
18. AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé). Argumentaire pour la prise en charge des patients dyslipidémiques. 2005. http://www.afssaps.fr/Recommandations-de-bonne- pratique/Prise-en-charge-dupatient-dyslipidemique-recommandations-de bonne-pratiques/%28language%29/fre-FR. Accessed December 2, 2009.
19. McCord J, Jneid H, Hollander JE, et al; American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation. 2008;117(14):1897-1907.
20. Anand SS, Islam S, Rosengren A, et al; INTERHEART Investigators. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29(7):932-940.
21. Ancelle-Park R. Expanded European AIDS case definition. Lancet. 1993;341(8842):441.
22. Bedimo R, Westfall A, Drechsler H, et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. Paper presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 20, 2009; Cape Town, South Africa. Abstract MoAb202.
23. Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-based Medicine: How to Practice and Teach EBM. 3rd ed. Edinburgh, Scotland: Churchill Livingstone; 2005.
24. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study. J Infect Dis. 2010;201(3):318-330.
25. Lefèvre C, Boccara F, Auclair M, Capeau J, Caron M. Some protease inhibitors induce human endothelial cell dysfunction and prelamin A accumulation. Scientific poster presented at: 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; November 6-8, 2008; London, England.
26. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009;50(4):367-374.
27. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1(1):e19. Accessed May 1, 2010.
28. Benson CA, Ribaudo H, Zheng E, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events (ACTGA5001/ALLRT study). Scientific poster presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Quebec, Canada. Abstract 721.
29. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49(10):1591-1601.
30. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11(2):130-136.
31. Mercier S, Gueye NF, Cournil A, et al. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr. 2009;51(2):224-230.
32. Calmy A, Hirschel B, Cooper D, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther. 2009;14(2):165-179.
33. Smith C. D:A:D Study Group. Association between modifiable and nonmodifiable risk factors and specific causes of death in the HAART era: the Data Collection on Adverse Events of Anti-HIV Drugs Study. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 11, 2009; Montreal, Quebec, Canada. Abstract 145.
34. El-Sadr WM, Lundgren JD, Neaton JD, et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count: guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296.